Get the Stockscreener App
57.98
0.03%
0.02
Rapt Therapeutics Inc stock is traded at $57.98, with a volume of 899.53K.
It is up +0.03% in the last 24 hours and up +0.64% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$57.96
Open:
$57.94
24h Volume:
899.53K
Relative Volume:
0.40
Market Cap:
$1.68B
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-19.01
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+0.10%
1M Performance:
+0.64%
6M Performance:
+397.68%
1Y Performance:
+564.91%
1-Day Range:
$57.94
$57.99
1-Week Range:
$57.89
$57.99
52-Week Range:
$5.6652
$57.99
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
57.98 | 1.68B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power PlayGSK (NYSE:GSK) - Benzinga
GSK acquisition of Rapt Therapeutics receives regulatory clearance in the US - MLex
RTW INVESTMENTS, LP Acquires Additional Shares in RAPT Therapeutics Inc - GuruFocus
Rapt Therapeutics stock hits 52-week high at 57.87 USD By Investing.com - Investing.com South Africa
Rapt Therapeutics stock hits 52-week high at 57.87 USD - Investing.com Australia
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Biggest stock movers Tuesday: NVDA, RAPT, MMM and more - MSN
RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Sets New 52-Week HighHere's Why - MarketBeat
Is RAPT Therapeutics Inc a speculative investmentStop Loss & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Small Cap Stocks To Watch NowFebruary 13th - MarketBeat
Best Pharmaceutical Stocks To Follow TodayFebruary 13th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short Interest - MarketBeat
Is RAPT Therapeutics Inc. stock vulnerable to regulatory risksEarnings Performance Report & Verified Swing Trading Watchlist - mfd.ru
Can RAPT Therapeutics Inc. withstand a market correctionCPI Data & AI Based Buy and Sell Signals - mfd.ru
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations - Intellectia AI
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? - Morningstar
Top Pharmaceutical Stocks To ConsiderFebruary 10th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Why did RAPT stock surge 63% in pre-market today? - MSN
Pharma deal value falls in January 2026 amid lower M&A activity: GlobalData - Express Pharma
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders - marketscreener.com
RAPT Therapeutics Proposed Sale to GSK Under Investigation - Intellectia AI
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month HighHere's Why - MarketBeat
GSK's Acquisition Highlights Trend Towards Convenience-Focused D - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-JHG, FOLD, RAPT, and EXAS - The Malaysian Reserve
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy - MSN
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—JHG, FOLD, RAPT, and EXAS - Morningstar
Rapt Therapeutics stock reaches 52-week high at $57.71 By Investing.com - Investing.com Nigeria
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 12-Month HighStill a Buy? - MarketBeat
Rapt Therapeutics stock reaches 52-week high at $57.71 - Investing.com
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal - MSN
GSK acquires RAPT Therapeutics for $2.2bn - MSN
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Biggest stock movers Tuesday: NVDA, RAPT, and more - MSN
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):